BSX | Boston scientific corporation - Stock Value & PE Ratio Analysis

3

24

15

Good Growth

AI analysis rates BSX with a higher value score of 4.
It is mainly due to stable revenue growth, along with stable company liquidity.
Over the past 3 months, BSX has maintained a consecutive value rating of 4.0, slightly higher than the rating of 3.4 over the past 3 years, indicating higher growth opportunities for enterprise value.
Compared to all stocks in the Health Care sector, BSX has a higher value rating.

BSX Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/04/25 (Weekly Update)

BSX Financial Forecast

Unit : USD

Update to 2025/5/4 (Quarterly Update)

BSX Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.75	33.9%	11.4%	4.66B	20.9%	2%	12.4%
2024Q3	0.7	27.3%	6.5%	4.56B	22.4%	3.2%	11.1%
2024Q2	0.63	26%	7.1%	4.21B	19.3%	4.2%	7.9%
2024Q1	0.62	17%	6.3%	4.12B	14.5%	2.3%	12.8%
2023Q4	0.56	19.1%	8.9%	3.86B	13.8%	4.7%	13.6%

Update to 2025/5/7 (Quarterly Update)

BSX Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

BSX Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of BSX from 2007/01 till Now

215.18%
Cumulative Return: 6.48%
Annual Return: 26.55%
Volatility: 0.24
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from January, 2007 to May, 2025. (Total Trades: 6)